AD is a chronic relapsing disease characterized by pruritis and chronic inflammatory skin changes, (1) which affects approximately 10–30% of children and as much as 10% of adults worldwide.(2) This condition has a great significant impact on morbidity and presents an outstanding social economic burden.(3) AD is a multifactorial disease that develop by interaction between these factors in a positive feedback cycle. Treatment of AD interrupts the causal pathway. Management with conventional therapies has been a challenge, but a novel biological treatment called dupilumab was recently approved for the treatment of moderate-to-severe AD, but this drug only achieved 40% clear skin in combination with TCs.(4). JAK inhibitors are another new drug family that inhibit JAK-signaling pathways, which involve JAK1, JAK2, JAK3 and TYK2. JAK inhibitors have been approved to treat inflammatory diseases like rheumatoid arthritis, and high attention is currently being focused on the clinical development of JAK inhibitors for the treatment of AD. Which are a possible treatment for certain disease that are related to lymphocyte activation, such as psoriasis, alopecia areata, vitiligo and AD. JAK inhibitors are available in topical and oral forms, thereby allowing more administration routes depending on the severity of AD, which ranges from mild to severe. Since JAK inhibitors are a new treatment modality in dermatology, the efficacy of this new medicine and the safety thereof are still being debated. A systematic review and metaâ€Âanalysis were done for all randomized clinical trials that evaluated JAK inhibitors for Atopic dermatitis to investigate their pooled efficacy and safety compared to placebo. Results might be useful as a milestone to develop a more accurate view of this medication and provide direction for further research.
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value
